Advaxis, Inc., (NASDAQ:ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has appointed Gregory T. Mayes to the new position of Executive Vice President and Chief Operating Officer.
Mr. Mayes joins Advaxis following the recent closing of a financing totaling $26.5 million and an uplisting to the NASDAQ Capital Market. Advaxis is now positioned to maximize the potential of its proprietary immunotherapy technology platform and focus its resources on advancing its lead product candidate, ADXS-HPV, into registrational studies for invasive cervical cancer.
Help employers find you! Check out all the jobs and post your resume.